Disease Markers

Table of Contents: 2013

  • Disease Markers -
  • Special Issue
  • Volume 34
  • - Article ID 341578

The Value of Combined Use of Survivin mRNA and Matrix Metalloproteinase 2 and 9 for Bladder Cancer Detection in Voided Urine

Sanaa Eissa | Soheir Badr | ... | Mohamed Esmat
  • Disease Markers -
  • Special Issue
  • Volume 34
  • - Article ID 798914

Common Oxytocin Receptor Gene Polymorphisms and the Risk for Preterm Birth

Lorenz Kuessel | Christoph Grimm | ... | Maximilian Schmid
  • Disease Markers -
  • Special Issue
  • Volume 34
  • - Article ID 302920

Maternal SNPs in the p53 Pathway: Risk Factors for Trisomy 21?

Juliano André Boquett | Ana Paula Carneiro Brandalize | ... | Lavínia Schuler-Faccini
  • Disease Markers -
  • Special Issue
  • Volume 34
  • - Article ID 246017
  • - Brief Communication

The Search for a Genetic Factor Associating with Immune Restoration Disease in HIV Patients Co-Infected with Mycobacterium tuberculosis

Jacquita S. Affandi | Manoj Kumar | ... | Patricia Price
  • Disease Markers -
  • Special Issue
  • Volume 34
  • - Article ID 512107

eNOS 4a/b Polymorphism and Its Interaction with eNOS G894T Variants in Type 2 Diabetes Mellitus: Modifying the Risk of Diabetic Nephropathy

Zohreh Rahimi | Ziba Rahimi | ... | Niloofar Yavari
  • Disease Markers -
  • Special Issue
  • Volume 34
  • - Article ID 659864

Psoriasin: A Novel Marker Linked Obesity with Psoriasis

Ragaa H. M. Salama | Hani A. Al-Shobaili | ... | Abdullateef A. Alzolibani
  • Disease Markers -
  • Special Issue
  • Volume 34
  • - Article ID 235056

eNOS Gene Variants and the Risk of Premature Myocardial Infarction

Aggeliki-Maria Zigra | Loukianos S. Rallidis | ... | Argyri Gialeraki
  • Disease Markers -
  • Special Issue
  • Volume 34
  • - Article ID 842130

Levels of PEDF in Pleural Effusions from Lung Adenocarcinoma and Benign Disease Patients

Nuria Sánchez-Otero | Sonia Blanco-Prieto | ... | Francisco Javier Rodríguez-Berrocal
  • Disease Markers -
  • Special Issue
  • Volume 34
  • - Article ID 951751

Utility of OCT3/4, TSPY and β-Catenin as Biological Markers for Gonadoblastoma Formation and Malignant Germ Cell Tumor Development in Dysgenetic Gonads

Icela Palma | Nayely Garibay | ... | Gloria Queipo
  • Disease Markers -
  • Special Issue
  • Volume 34
  • - Article ID 587682

HER1 R497K and HER2 I655V Polymorphisms Are Linked to Development of Breast Cancer

Naglaa R. AbdRaboh | Hanan H. Shehata | ... | Fatehia A. Bayoumi
  • Disease Markers -
  • Special Issue
  • Volume 34
  • - Article ID 420914

Expression of Matrix Metalloproteinases in Human Breast Cancer Tissues

Chellakkan Selvanesan Benson | Somasundaram Dinesh Babu | ... | Bhaskaran Ravi Sankar
  • Disease Markers -
  • Special Issue
  • Volume 34
  • - Article ID 728410

MRP1 but Not MDR1 Is Associated with Response to Neoadjuvant Chemotherapy in Breast Cancer Patients

Mohsen Taheri | Frouzandeh Mahjoubi
  • Disease Markers -
  • Special Issue
  • Volume 34
  • - Article ID 856750

Prognostic Role of microRNA-155 in Various Carcinomas: Results from a Meta-Analysis

Jing He | Fengmei Zhang | ... | Yulan Zhao
  • Disease Markers -
  • Special Issue
  • Volume 34
  • - Article ID 794927

Immunohistochemiluminescence Detection: A Quantitative Tool in Breast Cancer HER-2 Status Evaluation

Moacyr Jesus Barreto de Melo Rêgo | Marina Ferraz Cordeiro | ... | Eduardo Isidoro Carneiro Beltrão
  • Disease Markers -
  • Special Issue
  • Volume 34
  • - Article ID 680302

CD99 and HLA-II Immunostaining in Breast Cancer Tissue and Their Correlation with Lymph Node Metastasis

Amal Baccar | Imen Ferchichi | ... | Amel Benammar Elgaaied
Disease Markers
 Journal metrics
See full report
Acceptance rate6%
Submission to final decision131 days
Acceptance to publication42 days
CiteScore3.700
Journal Citation Indicator-
Impact Factor-
 Submit Check your manuscript for errors before submitting

We have begun to integrate the 200+ Hindawi journals into Wiley’s journal portfolio. You can find out more about how this benefits our journal communities on our FAQ.